CYP3A4 and CYP2C19 genetic polymorphisms and zolpidem metabolism in the Chinese Han population: A pilot study

Forensic Science International

Volumn 227, Issue 1-3, 2013, Pages 77-81

  Shen, Min ^a   Shi, Yan ^a,b   Xiang, Ping ^a  

^a INSTITUTE OF FORENSIC SCIENCE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

CYP2C19; CYP3A4; Zolpidem metabolism

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM 6 CARBOXYLIC ACID; ZOLPIDEM PHENYL 4 CARBOXYLIC ACID;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; DIPLOPIA; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FORENSIC TOXICOLOGY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LETHARGY; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOMITING;

ALLELES; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; FORENSIC TOXICOLOGY; GENOTYPE; HUMANS; HYPNOTICS AND SEDATIVES; MASS SPECTROMETRY; MUTATION; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES;

EID: 84875627430     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2012.08.035     Document Type: Article

References (26)

1. LeBeau M.A., Montgomery M.A. Challenges of drug facilitated sexual assault. Forensic Sci. Rev. 2010, 22:1-6.
2. Villain M., Chèze M., Tracqui A., Ludes B., Kintz P. Windows of detection of zolpidem in urine and hair: application to two drug facilitated sexual assaults. Forensic Sci. Int. 2004, 143:157-161.
3. Kintz P., Villain M., Dumestre-Toulet V., Ludes B. Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/MS A case involving zolpidem. J. Clin. Forensic Med. 2005, 12:36-41.
4. Criswell H.E., Simson P.E., Knapp D.J. Effect of zolpidem on gamma-aminobutyric acid (GABA)-induced inhibition predicts the interaction of ethanol with GABA on individual neurons in several rat brain regions. J. Pharmacol. Exp. Ther. 1995, 273:526-536.
5. Holm K.J., Goa K.L. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000, 59:865-889.
6. Lancel M. Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep 1999, 22:33-42.
7. Garnier R., Guerault E., Muzard D., Azoyan P., Chaumet-Riffaud A.E., Efthymiou M.L. Acute zolpidem poisoning-analysis of 344 cases. J. Toxicol. Clin. Toxicol. 1994, 32:391-404.
8. Gock S.B., Wong S.H., Nuwayhid N., Venuti S.E., Kelley P.D., Teggatz J.R. Acute zolpidem overdose-report of two cases. J. Anal. Toxicol. 1999, 23:559-562.
9. Kuzniar T.J., Balagani R., Radigan K.A., Factor P., Mutlu G.M. Coma with absent brainstem reflexes resulting from zolpidem overdose. Am. J. Ther. 2010, 17:172-174.
10. Levine B., Wu S.C., Smialek J.E. Zolpidem distribution in postmortem cases. J. Forensic Sci. 1999, 44:369-371.
11. Meeker J.E., Som G.M., Macapagal G.M., Benson P.A. Zolpidem tissue concentrations in a multiple drug related death involving Ambien. J. Anal. Toxicol. 1995, 19:531-534.
12. Tracqui A., Kintz P., Mangin P. A fatality involving two unusual compounds-zolpidem and acepromazine. Am. J. Forensic Med. Pathol. 1993, 14:309-312.
13. Saari T.I., Laine K., Leino K., Valtonen M., Neuvonen P.J., Olkkola K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br. J. Clin. Pharmacol. 2006, 63:116-120.
14. Fraisse J., Garrigou-Gadenne D., Thènot J.P. Pharmacokinetic and metabolic profiles of zolpidem. Zolpidem: An Update of its Pharmacological Properties and Therapeutic Place in the Management of Insomnia 1996, 45-57. Elsevier, Paris. H. Freeman, A.J. Puech, T. Roth (Eds.).
15. Von Moltke L.L., Greenblatt D.J., Granda B. Zolpidem metabolism in vitro: responsible cytochromes chemical inhibitors and in vivo correlations. Br. J. Clin. Pharmacol. 1999, 48:89-97.
16. Pichard L., Gillet G., Bonfils C. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab. Dispos. 1995, 23:1253-1262.
17. Swainston H.T., Keatin G.M. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005, 19:65-89.
18. Shi J., Guo T., Xia D. Population pharmacokinetics of zolpidem tartrate tablets in healthy volunteers of five different nationalities in China. Chin. Pharm. J. 2011, 46:850-856.
19. Xiao Y., Yang L., Xia D. A comparation of pharmacokinetics of zolpidem tartrate between Hui and Han healthy volunteers. Pharm. J. Chin. PLA 2011, 27:233-235.
20. Zhang L., Luan Y., Du H. Analysis of zolpidem in blood by solid phase extraction and gas chromatography. Forensic Sci. Technol. 2010, 2:28-30.
21. Vlase L., Popa A., Neag M., Muntean D., Bâldea I., Leucuta S.E. Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J. Clin. Pharmacol. 2011, 51:1233-1236.
22. Shi Y., Xiang P., Li L., Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci. Int. 2011, 207:183-187.
23. Weinling E., McDougall S., Andre F. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam. Clin. Pharmacol. 2006, 20:397-403.
24. Drover D., Lemmens H., Naidu S. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin. Ther. 2000, 22:1443-1461.
25. Weinshiboum R. Inheritance and drug response. N. Engl. J. Med. 2003, 348(6):529-537.
26. Koski A., Sistonen J., Ojanpera I. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci. Int. 2006, 158:177-183.